Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.714833 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.714833 34745093!8564175!34745093     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 714833 Nephropedia Template TP {{tp|p=34745093|t=2021. Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19 |pdf=|usr=}}{{34745093}} gab.com Text Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19 JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34745093 #FOAvip BACKGROUND: The most severe cases of Coronavirus-Disease-2019 (COVID-19) develop into Acute Respiratory Distress Syndrome (ARDS). It has been proposed that oxygenation may be inhibited by extracellular deoxyribonucleic acid (DNA) in the form of neutrophil extracellular traps (NETs). Dornase alfa (Pulmozyme, Genentech) is recombinant human deoxyribonuclease I that acts as a mucolytic by cleaving and degrading extracellular DNA. We performed a pilot study to evaluate the effects of dornase alfa in patients with ARDS secondary to COVID-19. METHODS: We performed a pilot, non-randomized, case-controlled clinical trial of inhaled dornase for patients who developed ARDS secondary to COVID-19 pneumonia. RESULTS: Improvement in arterial oxygen saturation to inhaled fraction of oxygen ratio (PaO(2)/FiO(2)) was noted in the treatment group compared to control at day 2 (95% CI, 2.96 to 95.66, P-value = 0.038), as well as in static lung compliance at days 3 through 5 (95% CI, 4.8 to 19.1 mL/cmH(2)O, 2.7 to 16.5 mL/cmH(2)O, and 5.3 to 19.2 mL/cmH(2)O, respectively). These effects were not sustained at 14 days. A reduction in bronchoalveolar lavage fluid (BALF) myeloperoxidase-DNA (DNA : MPO) complexes (95% CI, -14.7 to -1.32, P-value = 0.01) was observed after therapy with dornase alfa. CONCLUSION: Treatment with dornase alfa was associated with improved oxygenation and decreased DNA : MPO complexes in BALF. The positive effects, however, were limited to the time of drug delivery. These data suggest that degradation of extracellular DNA associated with NETs or other structures by inhaled dornase alfa can be beneficial. We propose a more extensive clinical trial is warranted. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT04402970. Twit Text FOAVip Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19 ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34745093 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34745093 #FOAvip English Wikipedia <ref>{{Cite pmid|34745093}}</ref> Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19 #MMPMID34745093 Holliday ZM; Earhart AP; Alnijoumi MM; Krvavac A; Allen LH; Schrum AG Front Immunol 2021[]; 12 (ä): 714833 PMID34745093show ga BACKGROUND: The most severe cases of Coronavirus-Disease-2019 (COVID-19) develop into Acute Respiratory Distress Syndrome (ARDS). It has been proposed that oxygenation may be inhibited by extracellular deoxyribonucleic acid (DNA) in the form of neutrophil extracellular traps (NETs). Dornase alfa (Pulmozyme, Genentech) is recombinant human deoxyribonuclease I that acts as a mucolytic by cleaving and degrading extracellular DNA. We performed a pilot study to evaluate the effects of dornase alfa in patients with ARDS secondary to COVID-19. METHODS: We performed a pilot, non-randomized, case-controlled clinical trial of inhaled dornase for patients who developed ARDS secondary to COVID-19 pneumonia. RESULTS: Improvement in arterial oxygen saturation to inhaled fraction of oxygen ratio (PaO(2)/FiO(2)) was noted in the treatment group compared to control at day 2 (95% CI, 2.96 to 95.66, P-value = 0.038), as well as in static lung compliance at days 3 through 5 (95% CI, 4.8 to 19.1 mL/cmH(2)O, 2.7 to 16.5 mL/cmH(2)O, and 5.3 to 19.2 mL/cmH(2)O, respectively). These effects were not sustained at 14 days. A reduction in bronchoalveolar lavage fluid (BALF) myeloperoxidase-DNA (DNA : MPO) complexes (95% CI, -14.7 to -1.32, P-value = 0.01) was observed after therapy with dornase alfa. CONCLUSION: Treatment with dornase alfa was associated with improved oxygenation and decreased DNA : MPO complexes in BALF. The positive effects, however, were limited to the time of drug delivery. These data suggest that degradation of extracellular DNA associated with NETs or other structures by inhaled dornase alfa can be beneficial. We propose a more extensive clinical trial is warranted. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT04402970. |*COVID-19 Drug Treatment[MESH] |Administration, Inhalation[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Case-Control Studies[MESH] |DNA/metabolism[MESH] |Deoxyribonuclease I/*therapeutic use[MESH] |Extracellular Traps/metabolism[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen Consumption/drug effects[MESH] |Peroxidase/metabolism[MESH] |Pilot Projects[MESH] |Recombinant Proteins/therapeutic use[MESH] |Respiratory Distress Syndrome/*drug therapy[MESH] |SARS-CoV-2/*physiology[MESH]Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Sy(epmc).pdf DeepDyve Pubget Overpricing